MeSH D055728 - primary myelofibrosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Mylan | Busulfan | Busulfan |  | 2018-07-13 |  |  |
| Novartis | Ruxolitinib | Jakavi |  | 2012-08-23 | $1,541 M | Q2/20-Q2/23 |
| Apotex | Busulfan | Busulfan |  | 2019-05-07 |  |  |
| Hospira | Busulfan | Busulfan |  | 2018-07-31 |  |  |
| Amneal Pharmaceuticals | Busulfan | Busulfan |  | 2017-12-18 |  |  |
| Bristol Myers Squibb | Fedratinib | Inrebic |  | 2021-02-08 | $110 M | Y2023 |
| Accord Healthcare | Busulfan | Busulfan |  | 2019-02-22 |  |  |
| Fresenius Kabi | Busulfan | Busulfan Fresenius Kabi |  | 2014-09-22 |  |  |
| CTI Biopharma | Pacritinib | Vonjo | 2028-05-05 | 2022-02-28 |  |  |
| Incyte | Ruxolitinib | Jakafi | 2026-12-12 | 2011-11-16 | $2,585.602 M | Q2/23-Q1/24 |
| Ruxolitinib | Opzelura | 2026-12-12 | 2021-09-21 | $367.036 M | Q2/23-Q1/24 |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
50%58/117
Phase 2
23%22/96
Phase 3
28%8/29
Approved: 5Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use